The PharmaLex Group, a specialist provider of Development Consulting & Scientific Affairs, Regulatory Affairs, Pharmacovigilance and Quality and Compliance services, has entered a strategic collaboration with Volv Global.
Christopher M de M Rudolf, Founder and CEO of Volv Global, said: “We are delighted to be working with PharmaLex on the development of their pharmacovigilance solutions. Our innovative technology has an open design and intuitive interface, ensuring it can easily integrate into existing PV platforms.”
The partnership will combine both PharmaLex and Volv’s respective capabilities. Volv uses advanced predictive technologies, unassisted machine learning, artificial intelligence paradigms and web-scale technologies to develop products and services, supporting a number of key areas.
This includes supporting the monitoring of adverse events recorded on web forums and public social media channels, regulatory intelligence platforms, patient identification for rare diseases and related services, as well as market access intelligence.
Dr Thomas Dobmeyer, CEO PharmaLex, said: “The increasing volume of relevant literature in the medico-scientific domain is a challenge. Embedded artificial intelligence and cognitive computing technology allows for increased efficiency, especially in the area of drug adverse event monitoring.”
Initially focusing on pharmacovigilance services, these added technologies will allow PharmaLex to provide its clients with an extra layer of innovative safety monitoring, ensuring all adverse events, recorded both officially and online, are formally recorded and analysed.
Dr Tilo Netzer, CEO PharmaLex, said: “AI is fast becoming a key tool within the pharma industry. We are excited to be developing this innovative technology to enable us to offer our clients added value.”